AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (779 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Editorial | Open Access

Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV‐471

Yu Rao1,2( )
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, State Key Laboratory of Molecular Oncology, Tsinghua University, Beijing, China
Beijing Key Laboratory of Targeted Protein Degradation and Molecular Glue Therapeutics, Tsinghua University, Beijing, China
Show Author Information

References

【1】
【1】
 
 
Cancer Innovation
Article number: e70068

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Rao Y. Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV‐471. Cancer Innovation, 2026, 5(3): e70068. https://doi.org/10.1002/cai2.70068

2

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

Received: 18 May 2026
Accepted: 18 May 2026
Published: 07 June 2026
© 2026 The Author(s). Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.